The United States House Committee on Oversight and Accountability is the main investigative committee of the United States House of Representatives.
United States House Committee on Oversight and Accountability Health Care and Financial Services Subcommittee
(US House Oversight - Health Care and Financial Services)
Public
Structural Relationships
-
United States House Committee on Oversight and Accountability
(US House Oversight) -
United States House Committee on Oversight and Accountability Health Care and Financial Services Subcommittee
(US House Oversight - Health Care and Financial Services)
US House Oversight - Health Care and Financial Services - Information Set
Observations
WSLCB - Executive Management Team
(December 14, 2023) - Summary
Agency leaders went over what they anticipated dealing with in 2024, including “high-THC” regulations, lab accreditation authority, medically endorsed stores, and social equity applicants.
WSLCB - Work Group - Cannabinoid Science - Public Meeting
(August 3, 2023) - Summary
Updates on two subgroups included a rehashing of why some technologies and testing regimes had been favored by a prior task force as staff looked ahead to finalizing recommendations.
US House Oversight - Health Care and Financial Services - Subcommittee Hearing
(July 27, 2023) - Summary
- USA
- United States House Committee on Oversight and Accountability Health Care and Financial Services Subcommittee (US House Oversight - Health Care and Financial Services)
A congressional committee heard how lack of federal rulemaking on CBD and hemp products contributed to endangering consumers through sale of unsafe hemp-derived cannabinoid products.